Characterizing Antibody-Drug Conjugates Using Micro Pillar Array Columns Combined with Mass Spectrometry (μPAC™-MS)
The use of micro pillar array columns (μPAC™) for characterizing antibody-drug-conjugates is presented. Kadcyla® (ado-trastuzumab emtansine) and, for comparison, Herceptin® (trastuzumab) tryptic digests were analyzed on a 200 cm μPAC™ C18 column and peaks eluting were detected by ultraviolet (UV) spectroscopy and high-resolution mass spectrometry (MS).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
If you don’t have an account you can:
REGISTER NOW – it’s FREE and always will be!
You will benefit from:
- Unlimited access to ALL articles including Application Notes
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login as a Guest or via Social Media
This will allow you to read this article but you will only have limited access to The Analytical Scientist.Login as Guest Facebook Google+ LinkedIn Twitter